IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.998
NA - Nord America 4.474
AS - Asia 3.574
SA - Sud America 760
Continente sconosciuto - Info sul continente non disponibili 322
AF - Africa 81
OC - Oceania 11
Totale 14.220
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.177
RU - Federazione Russa 2.676
SG - Singapore 1.219
CN - Cina 1.197
IT - Italia 776
BR - Brasile 613
HK - Hong Kong 381
RO - Romania 347
VN - Vietnam 332
SE - Svezia 274
DE - Germania 234
FR - Francia 182
GB - Regno Unito 158
CA - Canada 132
BD - Bangladesh 119
FI - Finlandia 96
IN - India 84
AR - Argentina 72
MX - Messico 64
PL - Polonia 59
ID - Indonesia 51
AT - Austria 43
NL - Olanda 36
ZA - Sudafrica 34
ES - Italia 31
IQ - Iraq 30
JP - Giappone 27
TR - Turchia 25
LT - Lituania 23
JM - Giamaica 22
EC - Ecuador 18
MA - Marocco 18
UA - Ucraina 16
CR - Costa Rica 14
GT - Guatemala 14
IE - Irlanda 14
VE - Venezuela 13
CO - Colombia 12
PK - Pakistan 12
AU - Australia 11
HN - Honduras 11
MY - Malesia 11
PH - Filippine 11
TT - Trinidad e Tobago 10
AE - Emirati Arabi Uniti 9
KZ - Kazakistan 9
PY - Paraguay 9
UZ - Uzbekistan 9
BE - Belgio 8
CL - Cile 8
EG - Egitto 8
NI - Nicaragua 8
SA - Arabia Saudita 8
UY - Uruguay 8
GP - Guadalupe 6
CW - ???statistics.table.value.countryCode.CW??? 5
IL - Israele 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
SV - El Salvador 5
DO - Repubblica Dominicana 4
KE - Kenya 4
RS - Serbia 4
AZ - Azerbaigian 3
CH - Svizzera 3
IR - Iran 3
PT - Portogallo 3
SI - Slovenia 3
TN - Tunisia 3
AL - Albania 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EE - Estonia 2
GH - Ghana 2
KR - Corea 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
UG - Uganda 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 13.894
Salva come PNG Salva come JPEG
Città #
Singapore 623
Ashburn 598
Moscow 529
San Jose 501
Hong Kong 373
Dallas 369
Milan 210
Council Bluffs 209
Shanghai 194
New York 186
Beijing 181
Hefei 152
Lauterbourg 135
Los Angeles 119
Ho Chi Minh City 107
Munich 98
Santa Clara 94
Phoenix 89
Princeton 80
Lawrence 79
São Paulo 69
Hanoi 64
Orem 57
Denver 50
Helsinki 47
Rome 47
Warsaw 45
Boardman 42
Nuremberg 42
London 40
Montreal 40
Miano 36
Brooklyn 35
Atlanta 33
Cesano Boscone 33
Chennai 31
Guangzhou 31
Turku 31
Stockholm 29
Naples 27
Houston 26
Poplar 26
Tokyo 26
Frankfurt am Main 25
Seattle 25
St Petersburg 24
Toronto 24
Falkenstein 23
Gatchina 23
Mexico City 23
Amsterdam 22
Chicago 22
Vienna 21
Da Nang 20
Manchester 20
Rio de Janeiro 20
Johannesburg 19
North Bergen 19
Shenzhen 17
Boston 16
Haiphong 16
Turin 16
Buffalo 15
Lappeenranta 15
Ankara 14
Brasília 14
San Francisco 14
Yekaterinburg 14
Baghdad 13
Belo Horizonte 13
Philadelphia 13
Tianjin 13
Guatemala City 12
Perm 12
Charlotte 11
Dublin 11
Florence 11
Jakarta 11
Mumbai 11
Nanjing 11
Pune 11
Querétaro 11
Barnet 10
Kingston 10
San José 10
Verona 10
Biên Hòa 9
Columbus 9
Dhaka 9
Las Vegas 9
New Delhi 9
Palermo 9
Tashkent 9
Washington 9
Bologna 8
Brussels 8
Cape Town 8
Hangzhou 8
Hải Dương 8
Memphis 8
Totale 6.638
Salva come PNG Salva come JPEG
Nome #
Monkeypox in a patient with undifferentiated connective tissue disease 260
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 259
Viral bloodstream detection in mpox patients: An observational multicentric study 243
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 222
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 211
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 192
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 189
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 161
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 148
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 146
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 146
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 142
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 141
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 137
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 133
HIV viral load monitoring during monkeypox virus infection among people with HIV 132
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 132
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 130
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 129
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 126
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 126
Mpox in people with past infection or a complete vaccination course: a global case series 125
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 124
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 121
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 118
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 118
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 117
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 117
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 116
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 115
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 115
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 114
Beyond stigma: Monkeypox infection in a 27-year-old woman 113
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 112
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 110
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 110
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 110
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 109
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 109
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 109
Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART 109
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 108
Isolated monkeypox proctitis among men who have sex with men 107
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 107
Persistent ocular mpox infection in an immunocompetent individual 107
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 105
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 103
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 102
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 102
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 102
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 102
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 102
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 102
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 100
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 99
B-cell subset alterations and correlated factors in HIV-1 infection 97
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 97
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 96
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 95
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 94
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 92
Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination 92
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 92
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 91
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 90
Two individuals with potential monkeypox virus reinfection 90
Role of multi-site sampling in the diagnosis of human Monkeypox 89
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 89
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 86
Real-life use of cidofovir for the treatment of severe monkeypox cases 85
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 85
Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives 83
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 83
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 81
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 80
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 80
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 79
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 79
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy 78
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 78
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 78
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 77
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 77
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 77
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 76
Ageing with HIV: a multidisciplinary review 76
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine 75
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 75
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 75
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 74
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 70
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 68
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 67
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 67
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART 67
Rapid improvement of severe Mpox lesions with oral tecovirimat 66
Immune recovery and T cell subset analysis during effective treatment with maraviroc 66
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 65
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 65
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 65
Totale 10.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202273 0 0 0 20 7 9 3 6 4 11 3 10
2022/2023469 178 99 20 2 1 42 48 56 9 5 4 5
2023/2024559 9 19 99 48 64 125 21 58 1 15 30 70
2024/20252.693 196 35 75 78 123 224 712 316 267 201 166 300
2025/20268.167 606 530 474 1.060 649 276 646 652 2.224 523 294 233
2026/20272.185 243 581 405 956 0 0 0 0 0 0 0 0
Totale 14.220